We're thinking about...

Meet the analyst

Keep learning

Comments (2)

Personalized Medicine

Ninety percent of prescription drugs don't work about 50% of the time.¹ But, more effective, more personalized medicine is becoming possible as the cost of decoding human DNA drops -- from $3 billion in 1993 to a few thousand dollars today.

Doctors will be able to predict the diseases you're likely to get long before they appear in lab tests and prescribe treatments tailored specifically to work based on your genetic make-up.

Pharmaceutical companies have already begun switching from mass-production to developing drugs custom-made to work for specific genetic profiles, a change that could transform their approach to everything from cancer and depression to heart disease and Alzheimer's.

Technology start-ups and insurance giants are creating tools that add genetic data to electronic medical records, making it possible for patients to shop for providers with the best results treating patients like them.

Because medical spending accounts for almost 20% of U.S. consumer spending,² this new, more patient-centric system could save the health care industry billions of dollars a year and create huge new investing opportunities throughout the economy.

Meet the analyst

Edward L. Yoon

Edward (“Eddie”) Yoon is a research analyst for Fidelity Asset Management. Fidelity Investments is a leading provider of investment management, retirement planning, portfolio guidance, brokerage, benefits outsourcing and other financial products and services to more than 20 million individuals, institutions and financial intermediaries. Mr. Yoon is responsible for coverage of health care equipment and supplies stocks and serves as the health care sector leader for Fidelity Asset Management.

Prior to joining Fidelity in July 2006, Mr. Yoon was an analyst for JP Morgan Asset Management from 2002 until 2006 and a co-fund manager for the firm from 2005 until 2006.

Born in 1980, Mr. Yoon received a bachelor of arts degree in business economics from Brown University in 2002.

Keep learning

In-Depth Coverage

Forbes
"A Drug Of Your Own"

McKinsey Quarterly
"The microeconomics of personalized medicine"

MedCity News
"Personalized medicine’s promise and challenges discussed at Duke forum"

New England Journal of Medicine
"The Path to Personalized Medicine"

New York Times
"Study Says DNA’s Power to Predict Illness Is Limited"

Wall Street Journal
"A Doctor in Your Pocket"

Wired
"Geneticist Runs Personalized Medicine Superstudy On Himself"

Videos

TEDx
Daniel Kraft: Medicine's future? There's an app for that

Books

The Language of Life: DNA and the Revolution in Personalized Medicine
by Francis S. Collins

The Decision Tree: Taking Control of Your Health in the New Era of Personalized Medicine
by Thomas Goetz

The Quest for the Cure: The Science and Stories Behind the Next Generation of Medicines
by Brent R. Stockwell

Organizations

Broad Institute

European Association for Predictive, Preventive and Personalised Medicine (EPMA)

The European Personalised Medicine Association (EPEMED)

National Human Genome Research Institute

Personalized Medicine Coalition

Comments

Permalink Submitted by Ron Pezzi on Wed, 07/04/2012 - 16:14

Yes. I want the insurance actuaries to know my genetic makeup so that they can adjust my premiums accordingly.

Permalink Submitted by Michael Fulton on Wed, 09/19/2012 - 08:26

"Yes. I want the insurance actuaries to know my genetic makeup so that they can adjust my premiums accordingly." Nondiscrimination laws have been in the works from genetic preconditioning since the concept of personalized medicine. That is a non-issue. I had the opportunity to visit a research lab in Seattle, WA who is designing systems to quickly and efficiently put personalized medicine into practice. Please read my article about it at http://discussted.blogspot.com/2012/09/susan-solomon-promise-of-research-with.html

We welcome your comments on this topic.

Please comply with our posting guidelines.

Page/Commenting Guidelines

Thank you for visiting Fidelity Investments' Thinking Big web page.

Keep in mind that communications in our industry are highly regulated. We may, in our sole discretion, remove comments for a variety of reasons.

Keep it on topic:
We request that you keep your comments focused on the topic of the video.

Keep it clean:
Please don't post comments that are unlawful, abusive, defamatory, disparaging, offensive, or that contain profanities.

Keep away from:
In your comments, please avoid specific mention or discussions about investment advice or products, specific securities or investments or trading strategies.

By posting comments on this page, you grant to the Fidelity Investments companies a perpetual, irrevocable, royalty-free, world-wide, transferable license to use, copy, publish, distribute and publicly display any such comments in any form or medium, whether electronic, written or otherwise, including on the Thinking Big webpage

Fidelity does not provide customer service or enable financial transactions through Thinking Big. You should never post personal, account or transaction information anywhere herein. For customer service, please visit Fidelity.com/contactus or call 1-800-FIDELITY.

You should read Facebook, Inc.'s privacy policy and terms of service, as they apply to your communications through this web page. Fidelity's privacy policy is at http://go.fidelity.com/privacy

Fidelity is not affiliated with Facebook, Inc. the Facebook, Inc. Service, or YouTube, LLC. Fidelity does not expressly or implicitly adopt or endorse any of the expressions, opinions or content posted by fans or any third-parties on this web page.. Fidelity does not adopt or endorse any posts by the public that contain, or refer to, products, services, advertisements, recommendations or statements, or any other content that may appear on this web page. No part of this page is intended to make a recommendation or state a testimonial for or about a security, service or product, or to provide investment, tax or any other advice.

Opinions, statements, or views posted by the public through their Facebook page to this webpage are communications by the persons posting them, and they are not adopted or endorsed by Fidelity and do not represent the views of Fidelity or its management or employees. Posts that describe opinions, views or experiences may not be representative or indicative of another's personal experience, and there is no guarantee of future performance or success. Anyone who posts a comment who may have a business relationship with Fidelity or other beneficial interest in commenting should be aware that he or she may have obligations to disclose that relationship or interest in his or her post. The contents of this webpage is not intended to provide legal, tax, investment or insurance advice. Nothing on this webpage should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Fidelity or any third party.

This web page is intended for US persons only.

If you believe that your work has been copied by a commenter in a way that constitutes copyright infringement, please click here to learn how to contact Fidelity's Agent for Notice of claims of copyright infringement.

Registered service marks appearing herein are the property of FMR LLC.

Third party marks appearing herein are the property of their respective owners.

Guarantees are subject to the claims-paying ability of the issuing insurance company.

Please remember investing involves risks, and the value of your investment will fluctuate over time and you may gain or lose money.

Past performance is no guarantee of future results.

Before investing, consider the investment objectives, risks, charges, and expenses of the fund, 529 plan or annuity and its investment options. Contact Fidelity for a prospectus or fact kit or, if available, a summary prospectus containing this information. Read it carefully.

Fidelity Brokerage Services LLC, member NYSE, SIPC, 900 Salem Street, Smithfield, RI 02917

614679.1.0

Big Data